SK1912002A3 - Torsemide polymorphs - Google Patents

Torsemide polymorphs Download PDF

Info

Publication number
SK1912002A3
SK1912002A3 SK191-2002A SK1912002A SK1912002A3 SK 1912002 A3 SK1912002 A3 SK 1912002A3 SK 1912002 A SK1912002 A SK 1912002A SK 1912002 A3 SK1912002 A3 SK 1912002A3
Authority
SK
Slovakia
Prior art keywords
torsemide
modification
solvent
adduct
mixture
Prior art date
Application number
SK191-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Judith Aronhime
David Leonov
Marko Kordova
Anchel Schwartz
Ben-Zion Dolitzky
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of SK1912002A3 publication Critical patent/SK1912002A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Details Of Garments (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)
SK191-2002A 1999-08-11 2000-08-11 Torsemide polymorphs SK1912002A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14830599P 1999-08-11 1999-08-11
US18312700P 2000-02-17 2000-02-17
US21527300P 2000-06-30 2000-06-30
PCT/US2000/022081 WO2001010441A1 (en) 1999-08-11 2000-08-11 Torsemide polymorphs

Publications (1)

Publication Number Publication Date
SK1912002A3 true SK1912002A3 (en) 2002-07-02

Family

ID=27386674

Family Applications (1)

Application Number Title Priority Date Filing Date
SK191-2002A SK1912002A3 (en) 1999-08-11 2000-08-11 Torsemide polymorphs

Country Status (24)

Country Link
US (1) US6465496B1 (hr)
EP (1) EP1207880A4 (hr)
JP (1) JP2003527319A (hr)
KR (1) KR20020025217A (hr)
CN (1) CN1378448A (hr)
AU (1) AU781461C (hr)
BG (1) BG106400A (hr)
CA (1) CA2379322A1 (hr)
CZ (1) CZ2002404A3 (hr)
DE (1) DE00957398T1 (hr)
ES (1) ES2204354T1 (hr)
HK (1) HK1046636A1 (hr)
HR (1) HRP20020120A2 (hr)
HU (1) HUP0204318A3 (hr)
IL (1) IL148031A0 (hr)
LT (1) LT5004B (hr)
MX (1) MXPA02001369A (hr)
NO (1) NO20020622L (hr)
PL (1) PL354262A1 (hr)
SI (1) SI20816A (hr)
SK (1) SK1912002A3 (hr)
TR (1) TR200200353T2 (hr)
WO (1) WO2001010441A1 (hr)
YU (1) YU9502A (hr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2410802A1 (en) * 2000-02-17 2002-09-06 Minutza Leibovici A stable pharmaceutical formulation comprising torsemide modification ii
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
HRP20000162B1 (en) 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
EP1397343A1 (en) 2001-05-31 2004-03-17 Orion Corporation Fermion Process for preparing sertraline hydrochloride polymorphic form ii
IN192178B (hr) 2001-08-03 2004-03-06 Ranbaxy Lab
US20030119882A1 (en) * 2001-10-22 2003-06-26 Markus Maegerlein Solid pharmaceutical composition containing torasemide
ITMI20020639A1 (it) * 2002-03-27 2003-09-29 Cosma S P A Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea
HRP20020603B1 (hr) * 2002-07-19 2008-11-30 Pliva D.D. Novi postupak za pripravu modifikacije i n-(1-metiletilaminokarbonil)-4-(3-metilfenilamino)-3-piridinsulfonamida
CA2424644A1 (en) * 2003-04-07 2004-10-07 David John Mckenzie Preparation of torasemide
ES2244324B1 (es) * 2004-03-25 2006-11-16 Ferrer Internacional, S.A. Composiciones diureticas de liberacion prolongada.
AT500576B1 (de) * 2004-07-28 2006-11-15 Sanochemia Pharmazeutika Ag Verfahren zur reindarstellung von kristallformen von torsemid
KR100845383B1 (ko) * 2004-12-24 2008-07-09 일동제약주식회사 토르세미드 변형체(ⅰ)의 제조방법
US20070122483A1 (en) * 2005-11-29 2007-05-31 Sharon Myers Fluocinolone acetonide drug substance polymorphic interconversion
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途
CN105949115A (zh) * 2016-05-26 2016-09-21 南京正科医药股份有限公司 一种新晶型托拉塞米
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法
CN117486789A (zh) * 2023-12-29 2024-02-02 江西中医药大学 一种托拉塞米共晶盐及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34672A (en) 1862-03-18 Improved convertible boat, bridge, and tent
US30633A (en) 1860-11-13 Improvement in fire-escapes
US4055650A (en) 1974-04-17 1977-10-25 A. Christiaens Societe Anonyme Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines
GB1477664A (en) 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
DE3529529A1 (de) 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
DE3623620A1 (de) 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
HRP980532B1 (en) * 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US6166045A (en) * 1998-06-02 2000-12-26 Roche Diagnostics Gmbh Torasemide of modification III
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
HRP20000162B1 (en) * 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
WO2001070226A1 (en) * 2000-03-20 2001-09-27 Teva Pharmaceutical Industries Ltd. Novel processes for preparing torsemide intermediate
HRP20000328A2 (en) * 2000-05-19 2002-02-28 Pliva Farmaceutska Ind Dionik Novel polymorph v of torasemide

Also Published As

Publication number Publication date
LT2002017A (en) 2002-11-25
YU9502A (sh) 2005-06-10
HK1046636A1 (zh) 2003-01-24
AU6902600A (en) 2001-03-05
BG106400A (en) 2002-08-30
IL148031A0 (en) 2002-09-12
CZ2002404A3 (cs) 2002-06-12
NO20020622D0 (no) 2002-02-08
HUP0204318A3 (en) 2005-03-29
KR20020025217A (ko) 2002-04-03
CN1378448A (zh) 2002-11-06
LT5004B (lt) 2003-03-25
EP1207880A1 (en) 2002-05-29
HUP0204318A2 (en) 2003-05-28
WO2001010441A1 (en) 2001-02-15
AU781461B2 (en) 2005-05-26
MXPA02001369A (es) 2005-08-26
TR200200353T2 (tr) 2002-06-21
PL354262A1 (en) 2003-12-29
ES2204354T1 (es) 2004-05-01
SI20816A (sl) 2002-08-31
DE00957398T1 (de) 2004-04-15
JP2003527319A (ja) 2003-09-16
HRP20020120A2 (en) 2003-10-31
EP1207880A4 (en) 2004-09-01
CA2379322A1 (en) 2001-02-15
NO20020622L (no) 2002-03-14
AU781461C (en) 2006-02-23
US6465496B1 (en) 2002-10-15

Similar Documents

Publication Publication Date Title
SK1912002A3 (en) Torsemide polymorphs
EP1511739B1 (en) Polymorphs of valsartan
US8329912B2 (en) Solid forms of 2-chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine
MX2007007301A (es) Polimorfos de clorhidrato de memantina.
WO2020014406A1 (en) Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
WO2003026586A2 (en) Pioglitazone hydrochloride
WO2007109799A2 (en) Polymorphs of eszopiclone malate
EP1507531B1 (en) Stable pharmaceutical compositions of desloratadine
KR20060015750A (ko) 지프라시돈 ＨＣｌ의 다형 형태 및 그 제조 방법
TW201829420A (zh) [(1S)-1-[(2S,4R,5R)-5-(5-胺基-2-酮基-噻唑并[4,5-d]嘧啶-3-基)-4-羥基-四氫呋喃-2-基]丙基]乙酸酯之新穎固態形式
WO2004085393A1 (en) Novel crystalline forms of tegaserod maleate
US20070260068A1 (en) Method for the Preparation of Crystal Forms of Torsemide in a Pure State
US6133269A (en) Polymorphic form of doxazosin mesylate (form II)
KR100659927B1 (ko) 다형태를갖는독사조신메실레이트의새로운형태(제iii형)
IL298629A (en) Methods and dosage forms for osmotic administration of pharmaceutical preparations containing deuterobenzene
CN111217807B (en) Dasatinib amorphous form and preparation method thereof
ZA200200967B (en) Tomsemide Polymorphs.
EP1950204A1 (en) Amorphous form of valsartan
EP1768969B1 (en) Crystalline mycophenolate sodium
EP1713769B1 (en) Amorphous tamsulosin hydrochloride
US9505792B2 (en) Forms of cidofovir
CN116969962A (zh) 一种酪氨酸激酶抑制剂的二马来酸盐的制备方法
CN111217807A (zh) 一种达沙替尼无定型及其制备方法
CN114560845A (zh) 喹啉化合物的晶型ɑ及其制备方法和应用
WO2006109318A1 (en) Novel polymorph of 3-hydroxy-3-(3’-sulfamyl-4’-chlorophenyl)phthalimidine